

HEALTHBANK HOLDINGS LIMITED
AND ITS SUBSIDIARIES
(Incorporated in the Republic of Singapore)
(Registration No: 201334844E)

Unaudited Condensed Interim Consolidated Financial Statements
For the six-month financial period ended 30 June 2023

Table of Contents

	Page
Condensed interim consolidated statement of comprehensive income	1
Condensed interim statements of financial position	2
Condensed interim statements of changes in equity	3
Condensed interim consolidated statement of cash flows	4
Notes to the condensed interim consolidated financial statements	5
Other information required by Appendix 7C of the Catalist Rules	12

This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "Sponsor"). This announcement has not been examined or approved by Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: +65 6232 3210) at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.

HealthBank Holdings Limited and its subsidiaries
Condensed interim consolidated statement of comprehensive income
For the six-month financial period ended 30 June 2023

	Note	The Group		Change %
		RMB'000		
		HY2023	HY2022	
Revenue	4	214	233	(8)
Other income		3	92	(97)
<i>Other losses:</i>				
Currency exchange loss, net		(316)	(206)	53
Waiver of loan interest to a non-related party		(681)	-	NM
		(997)	(206)	>100
Depreciation of property, plant and equipment		(1)	(3)	(67)
Employee compensation	6	(681)	(712)	(4)
Finance costs		-	(275)	NM
Other expenses		(669)	(976)	(31)
Total expenses		(1,351)	(1,966)	(31)
Loss before income tax		(2,131)	(1,847)	15
Income tax expenses	7	-	-	-
Loss for the financial period		(2,131)	(1,847)	15
Other comprehensive income				
<i>Items that may be reclassified subsequently to profit or loss:</i>				
Currency translation differences arising from consolidation		343	460	(25)
Other comprehensive income, net of tax		343	460	(25)
Total comprehensive loss for the financial period		(1,788)	(1,387)	29
(Loss)/profit attributable to:				
Equity holders of the Company		(2,144)	(1,850)	16
Non-controlling interests		13	3	>100
		(2,131)	(1,847)	15
Total comprehensive (loss)/income attributable to:				
Equity holders of the Company		(1,801)	(1,390)	30
Non-controlling interests		13	3	>100
		(1,788)	(1,387)	29
Loss per share attributable to equity holders of the Company (RMB cents per share):				
Basic		(2.27)	(2.37)	(4)
Diluted		(2.27)	(1.80)	26

NM: Not meaningful

The accompanying notes form an integral part of the condensed interim consolidated financial statements.

HealthBank Holdings Limited and its subsidiaries
Condensed interim statements of financial position
As at 30 June 2023

	Note	Group		Company	
		30 Jun 23 RMB'000	31 Dec 22 RMB'000	30 Jun 23 RMB'000	31 Dec 22 RMB'000
ASSETS					
Current assets					
Cash and bank balances		2,278	2,737	1,904	2,370
Other receivables		22	9,543	1,046	10,507
		2,300	12,280	2,950	12,877
Non-current assets					
Financial assets, at FVTPL	10	49,100	49,100	-	-
Investment in subsidiary corporations	11	-	-	44,800	44,800
Other receivables		7,766	-	7,766	-
Plant and equipment		5	6	5	6
		56,871	49,106	52,571	44,806
Total assets		59,171	61,386	55,521	57,683
LIABILITIES					
Current liabilities					
Other payables		883	1,310	544	942
NET ASSETS		58,288	60,076	54,977	56,741
EQUITY					
Capital and reserves attributable to equity holders of the Company					
Share capital	12	37,507	37,507	37,507	37,507
Currency translation reserve		4,975	4,632	5,068	4,692
Retained profits		15,814	17,958	12,402	14,542
		58,296	60,097	54,977	56,741
Non-controlling interests		(8)	(21)	-	-
Total equity		58,288	60,076	54,977	56,741

The accompanying notes form an integral part of the condensed interim consolidated financial statements.

HealthBank Holdings Limited and its subsidiaries
Condensed interim statements of changes in equity
For the six-month financial period ended 30 June 2023

The Group	Share Capital	Equity Component of Convertible Loan	Currency Translation Reserve	Retained Profits	Non-Controlling Interests	Total
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
At 1 January 2023	37,507	-	4,632	17,958	(21)	60,076
Total comprehensive income/(loss) for the financial period	-	-	343	(2,144)	13	(1,788)
At 30 June 2023	37,507	-	4,975	15,814	(8)	58,288
At 1 January 2022	29,194	1,442	4,020	28,368	31	63,055
Issuance of shares	1,933	-	-	-	-	1,933
Total comprehensive income/(loss) for the financial period	-	-	460	(1,850)	3	(1,387)
Redemption of convertible loans	-	(343)	-	-	-	(343)
At 30 June 2022	31,127	1,099	4,480	26,518	34	63,258

The Company	Share Capital	Equity Component of Convertible Loan	Currency Translation Reserve	Retained Profits	Total
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
At 1 January 2023	37,507	-	4,692	14,542	56,741
Total comprehensive income/(loss) for the financial period	-	-	376	(2,140)	(1,764)
At 30 June 2023	37,507	-	5,068	12,402	54,977
At 1 January 2022	29,194	1,442	3,971	19,193	53,800
Issuance of shares	1,933	-	-	-	1,933
Total comprehensive income/(loss) for the financial period	-	-	513	(1,173)	(660)
Redemption of convertible loans	-	(343)	-	-	(343)
At 30 June 2022	31,127	1,099	4,484	18,020	54,730

HealthBank Holdings Limited and its subsidiaries
Condensed interim consolidated statement of cash flows
For the six-month financial period ended 30 June 2023

	HY2023 RMB'000	HY2022 RMB'000
Cash flows from operating activities:		
Loss before income tax for the financial period	(2,131)	(1,847)
Adjustments for:		
Depreciation of plant and equipment	1	3
Unwinding of discount on convertible loans	-	57
Unrealised currency translation differences	343	460
Operating cash flows before movements in working capital	(1,787)	(1,327)
Change in working capital:		
Receivables	721	25
Payables	(427)	145
Net cash used in operating activities	(1,493)	(1,157)
Cash flows from investing activity:		
Repayment from non-related party	1,034	-
Net cash generated from investing activity	1,034	-
Cash flows from financing activities:		
Proceeds from issuance of share capital	-	1,933
Redemption of convertible loans	-	(2,329)
Net cash used in financing activities	-	(396)
Net decrease in cash and cash equivalents	(459)	(1,553)
Cash and cash equivalents at beginning of financial period	2,737	7,909
Cash and cash equivalents at end of financial period	2,278	6,356

1. General information

HealthBank Holdings Limited (the “**Company**”) is listed on the Catalist of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) and incorporated and domiciled in Singapore. The address of its registered office is 15 Scotts, 15 Scotts Road, #04-08, Suite 22, Singapore 228218.

The principal activity of the Company is investment holding. The principal activities of its subsidiary corporations are investment holdings, property investment and facilities management services.

2. Basis of preparation

The condensed interim consolidated financial statements for the six months ended 30 June (“**HY**”) 2023 have been prepared in accordance with SFRS(I) 1-34 *Interim Financial Reporting* issued by the Accounting Standards Council Singapore. The condensed interim consolidated financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last audited annual financial statements for the year ended 31 December 2022.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with Singapore Financial Reporting Standards (International) (“**SFRS(I)s**”), except for the adoption of new and amended standards as set out in Note 2.1.

Items included in the financial statements of each entity in the Group are measured using the currency of the primary economic environment in which the entity operates (“**functional currency**”). The Company’s functional currency is Singapore Dollar (“**SGD**” or “**S\$**”). The financial statements are presented in Chinese Renminbi (“**RMB**”) as the presentation currency of the Group.

2.1 Interpretations and amendments to published standards effective in 2023

On 1 January 2023, the Group has adopted the new or amended SFRS(I)s and Interpretations of SFRSs (“**INT SFRS(I)s**”) that are mandatory for application for the financial period.

The adoption of these new or amended SFRS(I)s and INT SFRS(I)s did not result in substantial changes to the accounting policies of the Group and the Company and had no material effect on the amounts reported for the current or prior financial period.

2.2. Critical accounting estimates, assumptions and judgements

In preparing the condensed interim consolidated financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the financial year ended 31 December 2022.

2. Basis of preparation (cont'd)

2.2. Critical accounting estimates, assumptions and judgements (cont'd)

Estimates, assumptions and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

(a) *Financial assets, at fair value through profit or loss ("FVTPL")*

The fair value of financial assets, at FVTPL is being assessed by using a variety of methods and assumptions based on market conditions, macro and microeconomic information that existing as at the reporting period.

(b) *Expected credit loss allowance for other receivables*

The Group has applied the general approach (12 months expected credit losses) in assessing the expected credit loss ("ECL") allowance for other receivables. In determining the ECL, the Group has assessed the probability of default and estimation of cash flows recoverable from the outstanding receivables.

As at each reporting date, the Group assesses whether the credit risk of a financial instruments has increased significantly since initial recognition. When credit risk has increased significantly since initial recognition, the loss allowance is measured at an amount equal to lifetime ECL.

3. Going Concern

In preparing the condensed interim consolidated financial statements, management has assessed the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

4. Segment and revenue information

The Group is organised into the following main business segments:

- a. HQ and other investing activities mainly relate to investment holding as well as Group level corporate services; and
- b. Property management mainly includes landscaping, property and facilities management services.

The Group's chief operating decision-maker ("CODM") comprises the Chief Executive Officer and Executive Directors. Management has determined the operating segments based on the reports reviewed by the CODM that are used to make strategic decisions, allocate resources and assess performance. The Chief Executive Officer and Executive Directors consider the business from both geographical and business segment perspectives.

4. Segment and revenue information

The CODM assesses the performance of the operating segments based on a measure of loss before interest, tax, depreciation and amortisation (“**Adjusted LBITDA**”). This measure basis excludes the effects of expenditure from the operating segments such as gains from disposal or impairment loss that are not expected to recur regularly in every period which are separately analysed. Interest income and finance expenses are not allocated to segments, as this type of activity is driven by the Group Treasury, which manages the cash position of the Group.

Sales between segments are carried out at market terms. The revenue from external parties reported to the CODM is measured consistent with that in the statement of comprehensive income.

4.1. Reportable segments

	HQ and Other		Property		Total	
	Investing Activities		Management			
	HY2023	HY2022	HY2023	HY2022	HY2023	HY2022
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Segment revenue	-	-	214	233	214	233
Adjusted LBITDA	(2,158)	(1,357)	28	(211)	(2,130)	(1,568)
Depreciation of property, plant and equipment	(1)	(2)	-	(1)	(1)	(3)
Finance costs	-	(275)	-	-	-	(275)
Government grant	-	57	-	-	-	57
Segment assets	58,997	70,639	174	791	59,171	71,430
Segment liabilities	(693)	(8,066)	(190)	(106)	(883)	(8,172)

HealthBank Holdings Limited and its subsidiaries
Notes to the condensed interim consolidated financial statements
For the six-month financial period ended 30 June 2023

4. Segment and revenue information (cont'd)

4.2. Disaggregation segments

	HQ and Other Investing Activities		Property Management	
	HY2023	HY2022	HY2023	HY2022
	RMB'000	RMB'000	RMB'000	RMB'000
Revenue				
People's Republic of China	-	-	214	233
Non-current assets				
People's Republic of China	56,866	64,727	-	-
Singapore	5	9	-	-
	56,871	64,736	-	-

5. Financial assets and financial liabilities

	Group		Company	
	30 Jun 2023	31 Dec 2022	30 Jun 2023	31 Dec 2022
	RMB'000	RMB'000	RMB'000	RMB'000
Financial assets				
Cash and bank balances	2,278	2,737	1,904	2,370
Financial assets, at FVTPL	49,100	49,100	-	-
Other receivables*	7,766	9,514	8,790	10,478
	59,144	61,351	10,694	12,848
Financial liabilities				
Other payables	(883)	(1,310)	(544)	(942)

* Excluded prepayments.

6. Related party transactions

In addition to the information disclosed elsewhere in the financial statements, the following transactions took place between the Group and related parties at terms agreed between the parties:

Key management personnel compensation is as follows:

	Group	
	HY2023 RMB'000	HY2022 RMB'000
<u>Directors</u>		
Wages and salaries	250	228
Employer's contribution to defined contribution plans, including Central Provident Fund	21	20
Fees	116	147
	387	395
<u>Other key management personnel</u>		
Wages and salaries	273	206
Employer's contribution to defined contribution plans, including Central Provident Fund	21	30
	294	236
	681	631

7. Taxation

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The Group recorded a loss before tax of RMB2.13 million in HY2023 and hence, income tax is not provided for the reporting period.

8. Dividends

No dividend is declared or recommended for HY2023 (HY2022: Nil) in view of the losses incurred in HY2023.

9. Net asset value

	Group		Company	
	30 Jun 23	31 Dec 22	30 Jun 23	31 Dec 22
Net asset value ("NAV") per ordinary share				
NAV attributable to equity holders of the Company (RMB'000)	58,296	60,097	54,977	56,741
Number of ordinary shares ('000)	94,300	94,300	94,300	94,300
NAV per ordinary share based on issued share capital (RMB)	0.62	0.64	0.58	0.60

10. Financial assets, at FVTPL

Fair value measurements

The table below presents assets and liabilities recognised and measured at fair value and classified by level of the following fair value measurement hierarchy:

- (a) quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1);
- (b) input other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices) (Level 2); and
- (c) inputs for the asset or liability that are not based on observable market data (unobservable inputs) (Level 3).

	<u>Level 1</u> RMB'000	<u>Level 2</u> RMB'000	<u>Level 3</u> RMB'000	<u>Total</u> RMB'000
Group				
30 June 2023				
Assets				
Financial assets, at FVTPL	-	-	49,100	49,100
31 December 2022				
Assets				
Financial assets, at FVTPL	-	-	49,100	49,100

As at 30 June 2023 and 31 December 2022, the financial assets, at FVTPL is representing the investment in unquoted equity. The fair value of financial assets is being assessed by using a variety of methods and assumptions based on market conditions, macro and microeconomic information that existing at each reporting period. Financial assets, at FVTPL is classified to Level 3 as significant unobservable inputs is used.

The fair value of current financial assets carried at amortised cost approximate their carrying amounts.

11. Investments in subsidiary corporations

Investments in subsidiary corporations are carried at cost less accumulated impairment losses in the Company's balance sheet. On disposal of such investments, the difference between disposal proceeds and the carrying amounts of the investments are recognised in profit or loss.

12. Share capital

	Group and Company			
	2023		2022	
	No. of shares	Issued and paid-up share capital	No. of shares	Issued and paid-up share capital
	'000	RMB'000	'000	RMB'000
1 January	94,300	37,507	78,000	29,194
Issuance of shares for cash consideration	-	-	3,800	1,933
30 June	94,300	37,507	81,800	31,127

All issued ordinary shares are fully paid. There is no par value for these ordinary shares. Fully paid ordinary shares carry one vote per share and carry a right to dividends as and when declared by the Company.

Pursuant to a share subscription exercise, the Company issued 3,800,000 ordinary shares at S\$0.105 per share on 30 June 2022 (equivalent to RMB1,933,000), to provide funds for the Group's general working capital purposes.

On 22 March 2021, the Company entered into a Convertible Loan Subscription Agreement with 3 non-related subscribers pursuant to which the Company had on 28 May 2021 issued to the subscribers unsecured convertible loan notes convertible at fixed conversion price of S\$0.088. As at 30 June 2022, the aggregate principal amount of the outstanding Convertible Loan is S\$1,700,000 (approximately RMB8.3 million).

Save as disclosed above, the Company did not have any outstanding options, convertibles, treasury shares and subsidiary holdings as at 30 June 2023 and 30 June 2022.

13. Subsequent events

There are no known subsequent events which have led to adjustments to this set of interim financial statements.

Other Information Required by Appendix 7C of the Catalist Rules

1. Review

The condensed interim statements of financial position of HealthBank Holdings Limited (the “**Company**”) and its subsidiaries (collectively, the “**Group**”) as at 30 June 2023 and the related condensed interim consolidated statement of comprehensive income, condensed interim statements of changes in equity and condensed interim consolidated statement of cash flows for the six-month period then ended and certain explanatory notes have not been audited or reviewed by the Company’s auditors.

The Group’s latest audited financial statements for the financial year ended 31 December 2022 were not subject to an adverse opinion, qualified opinion or disclaimer of opinion.

2. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group’s business

REVIEW OF FINANCIAL PERFORMANCE

Revenue

The Group recorded revenue of RMB214,000 in HY2023 from a facility and landscaping management service contract for the Atlantis Garden Project where the Group has 8% indirect effective equity interest in the said project.

Other income

Significant decrease in other income by RMB89,000 is mainly due to the absence of government grant and one-off employee serving short notice during the financial period.

Other losses

Increase in other losses mainly due to the waiver of loan interest to a non-related party in 1H2023. There was no waiver of loan interest in 1H2022.

Employee compensation

The employee compensation decreased by RMB31,000 in HY2023 as compared to HY2022 is mainly due to lower staff costs incurred in 1H2023 attributed to the disposal of a subsidiary corporation, HealthBank Technology Development (Liaoning) Limited on 22 July 2022.

Finance costs

No finance costs incurred in HY2023 due to the redemption of convertible loans in FY2022.

Other expenses

The decrease in other expenses of RMB307,000 is mainly due to the lower operating costs attributed to the disposal of a subsidiary corporation, HealthBank Technology Development (Liaoning) Limited on 22 July 2022.

2. **A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business (cont'd)**

Income tax expense

No income tax is provided for HY2023 as the Group recorded a loss before tax in HY2023.

REVIEW OF FINANCIAL POSITION

Current assets

Cash and bank balances decreased by RMB0.46 million, from RMB2.74 million as at 31 December 2022 to RMB2.28 million as at 30 June 2023. Please refer to the "Review of Cash Position" section below for further details on the material cash movements.

As at 30 June 2023, the Group has other receivables of RMB0.02 million, a decrease of RMB9.52 million from RMB9.54 million as at 31 December 2022 mainly due to reclassification of loan to non-related party from current assets to non-current assets due to the loan extension and amortisation of prepayments.

Non-current assets

Non-current assets increased by RMB7.77 million to RMB56.87 million as at 30 June 2023, mainly due to the reclassification of loan to non-related party from current assets to non-current assets due to the loan extension.

Current liabilities

Other payables decreased by RMB0.43 million to RMB0.88 million as at 30 June 2023 from RMB1.31 million as at 31 December 2022, mainly due to the payment of accrued expenses in FY2022.

REVIEW OF CASH POSITION

The net cash used in operating activities of RMB1.49 million was due to operating cash outflows before movement in working capital of RMB1.79 million and net cash outflow in operating activities of RMB0.29 million.

The net cash generated from investing activities of RMB1.03 million was due to the repayment of loan from non-related party.

The above resulted in the overall decrease of RMB0.46 million during the financial period.

The Group has cash and cash equivalents of RMB2.28 million as at 30 June 2023.

3. **Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.**

Not applicable. No forecast or prospect statement disclosed to shareholders previously.

4. **A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next reporting period and the next 12 months.**

Due to uncertainty in the economic recovery post-COVID-19 pandemic, the impact of China government's cooling measures on property sector, as well as lower home buyer confidence in China, the business environment will remain challenging for the financial year.

Despite all these challenges, the Group will continue to strive for improvement in our current business and explore new business opportunities with suitable business partners to collaborate and broaden our revenue stream to improve the Group's performance.

5. **If a decision regarding dividend has been made:**

- (a) **Whether an interim (final) dividend has been declared (recommended)**

No dividend is declared for the current financial period reported on.

- (b) (i) **Amount per share in cents**

Not applicable.

- (ii) **Previous corresponding period in cents**

No dividend is declared for the corresponding period.

- (c) **Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated)**

Not applicable.

- (d) **The date the dividend is payable**

Not applicable.

- (e) **The date on which Registrable Transfers received by the company (up to 5.00pm) will be registered before entitlements to the dividend are determined**

Not applicable.

6. If the Group has obtained a general mandate from shareholders for interested persons transactions (“IPT”) the aggregate value of such transactions as required under Rule 920(1)(a)(ii) of the Catalist Rules. If no IPT mandate has been obtained, a statement to that effect.

The Group has not obtained a general mandate from shareholders for IPT. There are no interested person transactions of S\$100,000 or more during the financial period under review.

7. Use of proceeds

Convertible Loan

The Company refers to its previous announcements dated 23 March 2021, 13 April 2021 and 28 May 2021 (“**Previous Announcements**”). Unless otherwise defined, all capitalised terms used in this section shall bear the same meaning as the capitalised terms used in the Previous Announcements.

The Company received Net Proceeds of S\$3.28 million raised from the Convertible Loans and the utilisation of the Net Proceeds since the last announcement released on 28 February 2023 up to the date of this announcement is as follows:

Use of Proceeds	Allocation	Redemption of convertible loan up to the date of this announcement	Amount utilised as at 28 February 2023	Amount utilised after 28 February 2023 up to the date of this announcement	Amount re-allocated ⁽⁴⁾	Balance amount as at the date of this announcement
	(S\$’000)	(S\$’000)	(S\$’000)	(S\$’000)	(S\$’000)	(S\$’000)
Business expansion and investment opportunities	2,480	(2,200) ⁽¹⁾	-	-	(280)	-
Working capital	800	-	(944) ⁽²⁾	(136) ⁽³⁾	280	-
Net Proceeds	3,280	(2,200)	(944)	(136)	-	-

7. Use of proceeds (cont'd)

Notes:

- (1) This pertains to payments made for (i) the redemption of the Convertible Loan amounting to S\$1.1 million as announced on 23 December 2021, (ii) partial redemption of the Convertible Loan amounting to S\$0.5 million as announced on 24 June 2022, and (iii) partial redemption of the Convertible Loan amounting to S\$0.6 million as announced on 19 September 2022.
- (2) This pertains to administrative expenses (approximately S\$559,000), salaries related expenses (approximately S\$378,000) and additional expenses for convertible loans (approximately S\$7,000).
- (3) This pertains to administrative expenses (approximately S\$32,000) and salaries related expenses (approximately S\$104,000).
- (4) As the Group required immediate funding for working capital purpose, it has re-allocated the funds from business expansion and investment opportunities to working capital purpose.

Save for the re-allocation, the above utilisations were consistent with the intended use of proceeds from the Convertible Loan as disclosed in the Previous Announcements.

Placement

The Company refers to its previous announcements dated 13 June 2022, 29 June 2022 and 30 June 2022 (“**Placement Announcements**”). Unless otherwise defined, all capitalised terms used in this section shall bear the same meaning as the capitalised terms used in the Placement Announcements.

The Company received net proceeds of S\$373,000 raised from the Placement. The status of the utilisation of the net proceeds as at the date of this announcement is as follows:

Use of Proceeds	Allocation	Amount utilised as at 28 February 2023	Amount utilised after 28 February 2023 up to the date of this announcement	Balance amount as at the date of this announcement
	(S\$'000)	(S\$'000)	(S\$'000)	(S\$'000)
Working capital	373	(159) ⁽¹⁾	(13) ⁽¹⁾	201

Note:

- (1) This pertains to payment for the professional fees with regards to the valuation fees and other due diligence incurred for a potential project in China.

The above utilisation was consistent with the intended use of proceeds from the Placement as disclosed in the Placement Announcements. The Company will continue to make periodic announcements on the utilisation of the balance of the net proceeds from the Placement.

8. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1) of the Catalist Rules

The Company has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1) of the Catalist Rules.

9. Additional information required pursuant to Rule 706A of the Catalist Rules

There were no acquisition or sale of shares in any of the Group's subsidiary or associated company nor incorporation or winding up or striking off of any subsidiary or associated company by the Company or any of the Group's entities during HY2023.

10. Negative confirmation by directors pursuant to Rule 705(5) of the Catalist Rules

The Board of Directors of the Company (the "Board") hereby confirms that, to the best of the Board's knowledge, nothing has come to the attention of the Board which may render the unaudited financial statement for the HY2023 to be false or misleading in any material aspect.

On behalf of the Board

Peng Fei
Executive Director and CEO
11 August 2023